JGP Global Gestao de Recursos Ltda. acquired a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,967 shares of the company's stock, valued at approximately $324,000. Zoetis comprises about 0.2% of JGP Global Gestao de Recursos Ltda.'s portfolio, making the stock its 23rd biggest position.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Navigoe LLC bought a new position in Zoetis in the fourth quarter valued at approximately $30,000. Cornerstone Planning Group LLC lifted its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after buying an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its stake in Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after buying an additional 120 shares in the last quarter. Sound Income Strategies LLC lifted its stake in Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after buying an additional 164 shares in the last quarter. Finally, Bfsg LLC lifted its stake in Zoetis by 614.6% in the first quarter. Bfsg LLC now owns 293 shares of the company's stock valued at $48,000 after buying an additional 252 shares in the last quarter. 92.80% of the stock is owned by institutional investors.
Insider Activity at Zoetis
In other news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president owned 15,129 shares in the company, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.18% of the stock is currently owned by corporate insiders.
Zoetis Trading Down 0.5%
Shares of Zoetis stock traded down $0.73 on Friday, reaching $147.51. 1,349,269 shares of the company's stock were exchanged, compared to its average volume of 3,117,052. The company has a market capitalization of $65.49 billion, a P/E ratio of 25.42, a price-to-earnings-growth ratio of 2.41 and a beta of 0.88. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The firm's 50-day moving average is $157.14 and its two-hundred day moving average is $159.94. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.
Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.56 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.
Zoetis Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis's payout ratio is currently 34.42%.
Analyst Upgrades and Downgrades
ZTS has been the topic of a number of research reports. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and cut their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Piper Sandler raised their price target on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, UBS Group decreased their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $204.63.
Check Out Our Latest Report on ZTS
Zoetis Profile
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles

Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.